Carina Biotech official launch
Carina Biotech celebrates its researchers, supporters and toasts to the future Last Friday, 2 November, Carina's MD Dr Justin Coombs and Chair Dr Leanna Read welcomed guests to UniSA's Pridham
A new CAR-T cell that attacks an atypical solid cancer antigen
Carina has developed a broad-spectrum but highly targeted CAR-T cell (CNA1003). CNA1003 is targeted to a specific marker that has been found on most cancer cells but has little to no
Gel formulation to deliver clinically effective doses of CAR-T cells to solid tumours and resection sites
Our researchers are working on the production of a thermoresponsive gel formulation that can be used to deliver CAR-T cells to tumour and/or resection sites. Instead of the CAR-T cells
Genetic ‘homing signal’ to attract CAR-T cells to solid tumours
Our research team at the University of Adelaide, led by Professor Shaun McColl, is developing a way to enable chemokine receptor mediated CAR-T active migration to solid tumours. Chemokines are small
New CAR-T cells that attack atypical solid cancer antigens
Carina Biotech is developing CAR-T cells targeted at molecular markers found on a broad range of cancer types but with little expression on healthy cells. Carina has lead CAR-T cells
CAR-T access technologies
Creating our targeted and cytotoxic CAR-T cells is only one part of our effort to produce a broad-spectrum CAR-T therapy. Carina Biotech scientists are working on 2 complementary technologies to significantly
CAR-T trial for solid tumours begins at Seattle Children’s in the United States
Carina Biotech is excited to see the beginning of a CAR-T solid tumour trial at Seattle Children’s Research Institute, our American-based research partners. The trial has been opened for children
The science behind CAR-T therapy
"A NEW AND UNIQUE WAY TO TREAT CANCER, CAR-T THERAPY IS POISED TO TRANSFORM THE OUTLOOK FOR CHILDREN AND ADULTS WITH CERTAIN OTHERWISE INCURABLE CANCERS." Chimeric Antigen Receptor
#1 Lack of ideal solid cancer antigen targets
The current CAR-T market is driven largely by CAR-T cells targeted against blood cancers and at only one antigen (CD19). Anti-CD19 CAR-T cells have consistently demonstrated high anti-tumour efficacy in
A history of CAR-T technology
“THESE CHIMERIC GENES HOLD PROMISE FOR THE IMMUNOTHERAPY OF CANCER." - Dr Zelig Eshhar 1989 CAR-T therapy is a revolutionary new cancer treatment option but its development has been